Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Last trade$68.27
Day change-$0.255 (-0.37%)
Day range$67.77 – $70.35
Volume1,341,168
Market cap$30.51B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$30.51B
Price / earnings
45.44×
Price / book
4.46×
Price / sales
11.66×
EV / sales
14.75×
EV / EBITDA
22.08×
Profitability
Earnings per share
$1.51
Return on assets
3.45%
Return on equity
9.82%
Dividend yield
1.34%
Liquidity and leverage
Debt / equity
1.26×
Current ratio
1.29×
Quick ratio
1.29×
Cash ratio
0.44×
Cash flow
Price / cash flow
10.31×
Price / free cash flow
10.31×
Free cash flow
$2.96B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RPRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$690.1M
$674.14M
$630.58M
$621.99M
$609.29M
$578.67M
$568.25M
$593.64M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$690.1M
$674.14M
$630.58M
$621.99M
$609.29M
$578.67M
$568.25M
$593.64M
Selling, general and administrative
$150.1M
$161.89M
$159.49M
$164.27M
$118.73M
$179.77M
$110.71M
$67.59M
Research and development
$63.16M
$97.85M
$39.79M
$50.5M
$50.5M
$300.5M
$50.5M
$500K
Total operating expenses
$279.27M
$541.02M
$67.54M
$233.61M
$182.14M
$368.87M
$34.07M
$232.13M
Operating income
$410.84M
$133.12M
$563.04M
$388.38M
$427.16M
$209.8M
$534.18M
$361.51M
Interest expense
-$90.49M
-$93.62M
-$93.72M
-$94.17M
-$79.56M
-$68.67M
-$65.26M
-$65.76M
Income before taxes
$266.64M
$81.49M
$468.26M
$355.91M
$440.21M
$92.64M
$434.43M
$334.35M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$266.64M
$81.49M
$468.26M
$355.91M
$440.21M
$92.64M
$434.43M
$334.35M
Net income attributable to common shareholders
$144.68M
$17.88M
$294.69M
$214.21M
$284.22M
$32.18M
$239.35M
$208.21M
EBITDA
$472.88M
$133.12M
$435M
$707.33M
$439.29M
$209.8M
$407.04M
-$206.91M
Basic earnings per share
$0.32
$0.04
$0.67
$0.50
$0.66
$0.08
$0.55
$0.47
Diluted earnings per share
$0.32
$0.04
$0.67
$0.38
$0.66
$0.07
$0.55
$0.35
Recent news
Company coverage with links to the original publishers.
Revolution Medicines' pancreatic cancer drug daraxonrasib received FDA approval and could generate peak revenues of $11 billion. Royalty Pharma, which financed the drug, stands to earn up to $340 million in peak royalties without doing the development work. While Revolution Medicines stock has surged 200% in the past year, Royalty Pharma offers a more diversified alternative with investments in 35 approved drugs and a 1.4% dividend yield.
Royalty Pharma (RPRX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and positive earnings estimate revisions.
Revolution Medicines reported Q3 2026 results with a narrower-than-expected loss of $1.90 per share and revenues of $197.6 million, entirely from Rasonque sales following its FDA approval in late August. The drug reached over 5,000 patients in five weeks with strong reimbursement coverage. The company maintained its 2026 operating expense guidance and holds a strong cash position of $3.7 billion. European approval is pending, and multiple late-stage studies are underway for pancreatic cancer and other RAS-mutant cancers.
Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.
Guardant Health is expected to report Q3 2026 earnings on November 5 with a consensus loss of $0.29 per share and revenues of $350.83 million (up 32.3% YoY). The company has a positive Earnings ESP of +4.76% combined with a Zacks Rank #3, suggesting it will likely beat consensus estimates. However, recent estimate revisions have been 6.86% lower over the last 30 days.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.235
Dec 10, 2026
recurring
Aug 14, 2026
$0.235
Sep 10, 2026
recurring
May 15, 2026
$0.235
Jun 10, 2026
recurring
Feb 20, 2026
$0.235
Mar 10, 2026
recurring
Nov 14, 2025
$0.22
Dec 10, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.